In vivo Efficacy Model for Cancer Research

Increase the predictivity of drug discovery

HOW IT WORKS

Companion animals can be used as a informative model in the preclinical development and discovery of novel cancer treatment.
 
Studies in dogs provide guidance for conducting similar investigation in human patients.
This model helps to evaluate the efficacy  and feasibility of new compounds and can inform the GO/NO-GO decision in clinical drug development.

Selected compound with anti-cancer activity demonstrated in vitro and mice studies 

We design and conduct 

companion animals trials in

our veterinary international

practices network

High predictivity

efficacy results

Go/No-Go Decision

Examples of Preclinical Investigation in Companion Animals 

Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).

FDA approved for human use

Acalabrutinib

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure.

Phase II human trial completed

Hydroxychloroquine

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.

FDA approved for human use

Ibrutinib

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity

Phase III human trials

Ganetespib

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Phase I human trials ongoing

NHS-IL12

Decision was made to not move forward with human studies based on companion animals trials results.

https://www.ncbi.nlm.nih.gov/books/NBK338437/

Human trials were not conducted

Sulphonamide PAC-1 or SPAC-1

Assessed single-agent activity and toxicity for development of tolerable dosing regimen.

Phase I human trials ongoing

PAC-1

Determined dosing regimen and supportive care protocols in companion animals. Identified adverse events, dose, and regimen.

Phase I human trials ongoing

KPT-335

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.

Phase I human trials ongoing

LMP400, LMP776 and LMP744

Studies in companion animals confirmed inhibition and tumor response. Important proof of concept study. Masitinib is EMA-approved for veterinary use.

Phase III human trials ongoing

Masitinib

Are you having problem to translate results from mice to human?

 
Less than 8% of compounds tested in mice models pass successfully human phase I clinical trial
Learn how our In vivo Efficacy Model for Cancer Research can increase the predictivity of drug discovery

 
 

Get in touch

Company Team

 

Lucas Rodrigues, DVM, MS, PhD

CEO & Scientific Director

lrodrigues@ridgeresearch.us

Mauricio Bauer, DVM, BVSc.,MBA

mbauer@ridgeresearch.us

 

Francisco Scacchetti, BBA

Chief Financial Officer

Bruce Truman

Strategic Adviser

btruman@bltconsulting.com

Contact

contact@ridgeresearch.us

Office

505 S. Rosa Road, Suite 225

Madison, WI 53719

© RIDGE RESEARCH 2016-2019